KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Total Debt (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Total Debt for 17 consecutive years, with $45.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Debt fell 9.14% to $45.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $45.1 billion, a 9.14% decrease, with the full-year FY2025 number at $45.1 billion, down 9.14% from a year prior.
  • Total Debt was $45.1 billion for Q4 2025 at Bristol Myers Squibb, down from $49.0 billion in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $55.7 billion in Q1 2024 to a low of $37.6 billion in Q3 2023.
  • A 5-year average of $45.0 billion and a median of $45.0 billion in 2022 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: dropped 15.88% in 2023, then surged 47.18% in 2024.
  • Bristol Myers Squibb's Total Debt stood at $44.6 billion in 2021, then fell by 11.75% to $39.3 billion in 2022, then rose by 1.15% to $39.8 billion in 2023, then rose by 24.83% to $49.6 billion in 2024, then dropped by 9.14% to $45.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Total Debt are $45.1 billion (Q4 2025), $49.0 billion (Q3 2025), and $49.2 billion (Q2 2025).